
The Histopathology and Treatment Strategies of Adenocarcinoma

Iman Mohammad Said Jallod¹, Aliaa Kareem Abdulla², Dhaneen Mahdi³, Ali A. Al-fahham⁴

¹Department of Basic Science Nursing, College of Nursing, University of Telafer, Telafer

²College of education for Pure Science, University of Babylon

³Department of Basic Science, College of Dentistry, University of Kufa, Iraq

⁴Faculty of Nursing, University of Kufa, Iraq

ABSTRACT: Adenocarcinoma is a cancer of glandular tissue and, therefore, poses considerable problems for diagnosis and treatment. The diverse nature of this cancer mandates a proper staging system for the guidance of treatment approaches for better patient outcomes. Advances in molecular biology, histopathology, and immunohistochemistry in recent years have contributed significantly to our understanding of adenocarcinoma, especially as it appears in the lung and gastrointestinal systems. This review attempts to synthesize the present knowledge about the classification of adenocarcinoma and the various treatment modalities with more stress on the clinical applications, while at the same time indicating areas that are not known and where further research should be directed.

INTRODUCTION

Adenocarcinoma is the most common classification of carcinomas derived from glandular tissue. Its biological characteristics make it impossible for the disease to be classified and also bring an impact on the prognosis as well. An accurate classification is required to offer appropriate cancer counseling that may also improve the clinical outcomes of patients. All these areas of examination substantially complement one another for an improved understanding and treatment of adenocarcinomas of the lung and alimentary canals. The present report enlists and synthesizes observations that were recently published, focusing on pertinent aspects in relation to classification of adenocarcinomas, an aftermath of which knowledge deficiencies and scopes for further studies can be identified (Heidenreich et al., 2014; Mottet et al., 2020).

Adenocarcinoma is a worst cancerous form because it initiates in glandular tissues and that is why it creates a great problem for its treatment due to the diverse nature of these tissues and different reactions to various therapies. The management of adenocarcinoma has been an emerging field over the last several years, with particular excellences in gastric, esophageal, and pancreatic adenocarcinomas underscoring the need for multimodal strategies (Biffi et al., 2018).

Thus, although considerable headway has been made in the classification of adenocarcinoma, several gaps in understanding remain. For instance, while the IASLC/ATS/ERS classification is more clarifying, the transition from earlier classifications poses a great problem in clinical settings, especially in marshaling treatment protocols between different institutional settings (Travis et al., 2015). More so, variations in interpreting histological findings may throw a spanner into the works leading to inconsistencies not only in the diagnosis but also the treatment.

Moreover, the relationship between adenocarcinoma subtypes and the tumor microenvironment still remains to be fully characterized. Although investigations into cancer-associated fibroblasts (CAFs) and their participation in tumor heterogeneity are beginning to emerge, extensive studies that define how they relate to different adenocarcinoma subtypes are necessary (Biffi et al., 2018). A better insight into such interaction may enhance the understanding of tumor behavior and resistance to treatment.

While there have been advances, substantial gaps exist in understanding the most appropriate therapeutic interventions for adenocarcinoma, and further studies are recommended to understand the long-term implications and possible resistance mechanisms 'while' associated with targeted therapies such as apatinib. Finally, as 'basically an art of application,' the integration of immunotherapy into conventionally available treatment protocols remains an area now needing much research, particularly in terms of markers that may show response and appropriate as well as a judiciously selected regimen.

Moreover, a need exists for further systematic research focusing on life quality and toxicity management related to treatment, notably under patients subjected to intensive chemotherapy protocols. Adverse effects associated with such treatments, like neutropenia in perioperative chemotherapy patients, underline the essentiality of proper monitoring and management of such toxicities for better patient care. (Ychou et al., 2011).

The Histopathology and Treatment Strategies of Adenocarcinoma

MOLECULAR AND HISTOPATHOLOGICAL CLASSIFICATION

The classification of a lung adenocarcinoma has been vastly improved as instituted within the classification of IASLC/ATS/ERS. The histomorphology subtypes focus on such grade this allowing different biological behaviors and even prognostic outcomes to be visibly identifiable by the healthcare providers (Travis et al., 2011). The terms adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) represents a change in the understanding of tumour development and patient prognosis. This was also done in an attempt to make clear diagnostic criteria and terminology especially in such categories as bronchioloalveolar carcinoma (BAC) that had remained unclear (Travis et al., 2011).

Molecular characterization in gastric adenocarcinoma: In gastric adenocarcinoma, molecular characterization has been detailed in order to identify different subtypes so that more precise therapeutic strategies can be used. The study conducted by Bass et al. (2014) stresses the complex genomic landscapes associated with gastric adenocarcinoma, unveiling unique molecular profiles associated with tumor behavior and response to treatment. Such classification enhances prognostic precision and clinical decision-making related mainly to targeted therapies.

PROGNOSTIC IMPLICATIONS AND SURVIVAL OUTCOMES

The classification of adenocarcinoma subtypes is really essential for prognosticating patient outcomes. Recent studies have demonstrated a very strong relationship between histopathologic subtypes and the survival rate. For instance, individuals diagnosed with AIS and MIA will show nearly 100% five-year survival rates. This is in sharp contradistinction to those with micropapillary-predominant and solid mucin-predominant adenocarcinomas, who experience much worse prognoses (Collisson et al., 2011). It underpins the need for proper classification to guide treatment approaches and improve strategies for managing patients.

Recent studies have reported that assessing mutations at the molecular level for EGFR and KRAS is very important for identifying patients who might benefit from targeted therapies. This study also said that after attaining molecular analysis to the classification system, it will allow provision with a much more personalized mode of treatment-the very latest in advancing into the era of precise medicine.

TREATMENT STRATEGIES FOR ADENOCARCINOMA

Perioperative Chemotherapy

Perioperative chemotherapy is playing a prominent role in the multimodal treatment of resectable gastroesophageal adenocarcinomas. Studies have disclosed that applying a pre-and post-chemotherapy combination of fluorouracil and cisplatin after the surgery showed much-improved OS and DFS rates as compared to the surgery alone group. This underlines the requirement for chemotherapy to be part of the surgical package, since it increases resection rates and survival outcomes for patients with this nasty pathology. (Ychou et al., 2011)

Furthermore, the FLOT regimen with docetaxel was significantly better compared to conventional ECF/ ECX in appreciating performance and survival end results of patients presenting with locally advanced resectable gastric and gastroesophageal junction adenocarcinomas. The increased efficacy of triple-chemotherapy regimens supports their adoption in general therapeutical principles, as a more intense assault on cancer cells would intuitively seem apt in view of the deplorably common advanced stages at presentation in these neoplasms.

Targeted Therapies

With the evolution of the available treatment modalities, the future belongs to targeted therapy in advanced adenocarcinoma. Notably, apatinib, an anti-VEGFR-2 targeted selective drug, showed promising results in patients with advanced gastric or gastroesophageal junction adenocarcinoma; the patients were heavily pre-treated with multiple chemotherapy regimens. The reported overall survival and progression-free survival improvements over placebo underline this necessity for individualized treatment programs incorporating targeted therapies in the management of late stages of this disease (Shaheen et al., 2016). Current recommendations of esophageal adenocarcinoma advocate a multidisciplinary approach including either preoperative chemoradiation or perioperative chemotherapy with available targeted therapies such as trastuzumab and ramucirumab. It stresses the direction of oncology towards personalized medicine in tailoring treatment plans according to molecular features of tumors, which may translate into better patient outcomes (Massad et al., 2013).

Immunotherapy

The CheckMate 649 trial tested the efficacy of first-line nivolumab in combination with chemotherapy as opposed to chemotherapy alone for advanced gastric and gastroesophageal junction adenocarcinoma. These study results give a good, strong recommendation for combining immunotherapy with standard chemotherapy, hinting that such combinations boost therapeutic efficacy and increase survival (Janjigian et al., 2021).

The Histopathology and Treatment Strategies of Adenocarcinoma

CONCLUSION

The histopathological and molecular frameworks have allowed newly classified adenocarcinoma to be much more advanced than the previous ones, with enhanced diagnostic accuracy, and personalization of treatment. Standardization of practices and bridging knowledge gaps, especially about the role of the tumor microenvironment, are thereby the challenges to take head-on. Future research efforts are to focus on these gaps for improving utility in classification and overall better patient care in adenocarcinoma management. The landscape of treatment for adenocarcinoma is one that is evolving toward multimodal personalized therapy with a measured combination of chemotherapy, targeted therapies, and immunotherapy. These findings lay a foundation for good management but further studies are crucial for filling the existing knowledge gaps and optimizing treatment outcomes for patients afflicted with this challenging disease. Further studies should focus on treatment protocol optimization, understood resistance mechanisms, and improved supportive care measures for overall adenocarcinoma management.

REFERENCES

- 1) Al-Batran, S., Homann, N., Pauligk, C., Goetze, T., Meiler, J., Kasper, S., Kopp, H., Mayer, F., Haag, G., Luley, K., Lindig, U., Schmiegel, W., Pohl, M., Stoeckl, J., Folprecht, G., Probst, S., Prasnika, N., Fischbach, W., Mahlberg, R., Trojan, J., Koenigsmann, M., Martens, U., Thuss-Patience, P., Egger, M., Block, A., Heinemann, V., Illerhaus, G., Moehler, M., Schenk, M., Kullmann, F., Behringer, D., Heike, M., Pink, D., Teschendorf, C., Lohr, Carmen., Bernhard, H., Schuch, G., Rethwisch, V., Weikersthal, L. F. V., Hartmann, J., Kneba, M., Daum, S., Schulmann, K., Weniger, J., Belle, S., Gaiser, T., Oduncu, F., Guntner, M., Hozaeel, W., Reichart, Alexander., Jäger, E., Kraus, T., Mönig, S., Bechstein, W., Schuler, M., Schmalenberg, H., & Hofheinz, R. (2019). Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. *The Lancet*, 393, 1948-1957. <http://doi.org/10.1002/bjs.11267>
- 2) Bass, A., Thorsson, V., Shmulevich, I., Reynolds, Sheila M., Miller, Michael., Bernard, Brady., Hinoue, T., Laird, P., Curtis, C., Shen, Hui., Weisenberger, D., Schultz, N., Shen, R., Weinhold, Nils., Kelsen, D., Bowlby, R., Chu, Andy., Kasaian, K., Mungall, A., Robertson, A. G., Sipahimalani, Payal., Cherniack, A., Getz, G., Liu, Yingchun., Noble, M., Pedamallu, C., Sougnez, C., Taylor-Weiner, A., Akbani, Rehan., Lee, Ju-Seog., Liu, Wenbin., Mills, G., Yang, Da., Zhang, Wei., Pantazi, A., Parfenov, Michael G., Gulley, M., Piazuelo, M., Schneider, B., Kim, Jihun., Boussioutas, A., Sheth, Margi., Demchok, John A., Rabkin, C., Willis, J., Ng, S., Garman, Katherine S., Beer, D., Pennathur, A., Raphael, Benjamin J., Wu, Hsin-Ta., Odze, R., Kim, H., Bowen, Jay., Leraas, K., Lichtenberg, T., Weaver, Stephanie., McLellan, M., Wiznerowicz, M., Sakai, R., Lawrence, M., Cibulskis, K., Lichtenstein, Lee T., Fisher, Sheila A., Gabriel, S., Lander, E., Ding, L., Niu, Beifang., Ally, Adrian., Balasundaram, M., Birol, I., Brooks, Denise., Butterfield, Y., Carlsen, R., Chu, Justin., Chuah, E., Chun, Hye-Jung E., Clarke, A., Dhalla, Noreen., Guin, R., Holt, R., Jones, Steven J. M., Lee, Darlene., Li, Haiyan., Lim, E., Ma, Yussanne., Marra, M., Mayo, Michael., Moore, Richard A., Mungall, K., Nip, K., Schein, J., Tam, Angela., Thiessen, N., Beroukhim, R., Carter, S., Cherniack, A., Cho, Juok., Dicara, D., Frazer, S., Gehlenborg, Nils., Heiman, David I., Jung, Joonil., Kim, Jaegil., Lin, Pei., Meyerson, M., Ojesina, A., Pedamallu, C., Saksena, G., Schumacher, S., Stojanov, P., Tabak, B., Voet, Douglas., Rosenberg, Mara W., Zack, Travis., Zhang, Hailei., Zou, L., Protopopov, A., Santoso, Netty G., Lee, Semin., Zhang, Jianhua., Mahadeshwar, Harshad S., Tang, Jiabin., Ren, X., Seth, S., Yang, Lixing., Xu, A. W., Song, Xingzhi., Xi, Ruibin., Bristow, C., Hadjipanayis, Angela., Seidman, J., Chin, L., Park, P., Kucherlapati, R., Ling, Shiyun., Rao, A., Weinstein, J., Kim, Sang-Bae., Lee, Ju-Seog., Lu, Yiling., Mills, G., Bootwalla, Moiz., Lai, Phillip H., Triche, T., Berg, D. J. Van Den., Baylin, S., Herman, J., Murray, Bradley A., Askoy, B. A., Ciriello, G., Dresdner, Gideon., Gao, Jianjiong., Gross, Benjamin E., Jacobsen, A., Lee, William., Ramirez, Ricardo., Sander, C., Şenbabaoğlu, Y., Sinha, Rileen., Sumer, S. O., Sun, Yichao., Thorsson, V., Iype, L., Kramer, R., Kreisberg, R., Rovira, Hector., Tasman, Natalie I., Ng, S. C., Haussler, D., Stuart, Josh M., Verhaak, R., Leiserson, Mark D. M., Taylor, B., Black, Aaron D., Carney, Julie., Gastier-Foster, J., Helsen, Carmen., McAllister, Cynthia., Ramirez, N., Tabler, Teresa R., Wise, L., Zmuda, E., Penny, R., Crain, D., Gardner, J., Lau, Kevin R., Curely, Erin., Mallery, D., Morris, S., Paulauskis, J., Shelton, T., Sherman, M., Benz, C., Lee, Jaehyuk., Fedosenko, K., Manikhas, G., Potapova, O., Voronina, Olga., Belyaev, S., Dolzhansky, Oleg., Rathmell, W., Brzeziński, Jakub., Ibbs, Matthew., Korski, Konstanty., Kycler, W., LaŹniak, Radoslaw., Leporowska, E., Mackiewicz, A., Murawa, D., Murawa, P., Spychała, A., Suchorska, W., Tatka, Honorata., Teresiak, M., Abdel-Misih, R., Bennett, Joseph., Brown, Jennifer., Iacocca, M., Rabeno, B., Kwon, S., Kemkes, A., Curley, Erin E., Alexopoulou, I., Engel, J., Bartlett, J., Albert, Monique., Park, D., Dhir, R., Luketich, J., Landreneau, R., Janjigian, Y., Cho, E., Ladanyi, M., Tang, Laura H., McCall, S., Park, Y. S., Cheong, J., Ajani, J., Camargo, M. C., Alonso, S., Ayala, Brenda., Jensen, M., Pihl, T., Raman, R., Walton, Jessica L., Wan, Yunhu., Eley, G., Shaw, K. R. Mills., Tarnuzzer, R., Wang, Zhining., Yang, Liming., Zenklusen, J., Davidsen, Tanja., Hutter, C., Sofia, H., Burton, R., Chudamani, Sudha., & Liu, Jia. (2014). Comprehensive molecular characterization of gastric adenocarcinoma. *Nature*, 513, 202-209

The Histopathology and Treatment Strategies of Adenocarcinoma

<http://doi.org/10.1038/nature13480>

- 3) Biffi, Giulia., Oni, Tobiloba E., Spielman, Benjamin P., Hao, Yuan., Elyada, Ela., Park, Youngkyu., Preall, Jonathan., & Tuveson, D. (2018). IL1-Induced JAK/STAT Signaling Is Antagonized by TGF β to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma. *Cancer discovery*, 9 2, 282-301. <http://doi.org/10.1158/2159-8290.CD-18-0710>
- 4) Collisson, E., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, Morgan L., Gu, Shenda., Cooc, J., Weinkle, Jennifer., Kim, Grace E., Jakkula, L., Feiler, H., Ko, A., Olshen, A., Danenberg, Kathleen., Tempero, M., Spellman, P., Hanahan, D., & Gray, J. (2011). Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy. *Nature medicine*, 17, 500 - 503. <http://doi.org/10.1038/nm.2344>
- 5) Denisenko, T., Budkevich, I., & Zhivotovsky, B. (2018). Cell death-based treatment of lung adenocarcinoma. *Cell Death & Disease*, 9 . <http://doi.org/10.1038/s41419-017-0063-y>
- 6) Dong, Z., Zhong, W., Zhang, Xuchao., Su, J., Xie, Z., Liu, S., Tu, H., Chen, Hua-jun., Sun, Yue-Li., Zhou, Qing., Yang, Jin-Ji., Yang, Xue-Ning., Lin, Jia-Xin., Yan, Hong-Hong., Zhai, Hao-ran., Yan, Li-xu., Liao, R., Wu, Si-pei., & Wu, Yi-long. (2016). Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. *Clinical Cancer Research*, 23 , 3012 - 3024 . <http://doi.org/10.1158/1078-0432.CCR-16-2554>
- 7) Elyada, Ela., Bolisetty, M., Laise, P., Flynn, W., Courtois, Elise T., Burkhart, R., Teinor, J., Belleau, P., Biffi, Giulia., Lucito, M., Sivajothi, S., Armstrong, T., Engle, Danielle D., Yu, Kenneth H., Hao, Yuan., fishman, elliot k., Park, Youngkyu., Preall, Jonathan., Jaffee, E., Califano, A., Robson, P., & Tuveson, D. (2019). Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts.. *Cancer discovery* . <http://doi.org/10.1158/2159-8290.CD-19-0094>
- 8) Hosein, A., Brekken, R., & Maitra, A. (2020). Pancreatic cancer stroma: an update on therapeutic targeting strategies. *Nature Reviews Gastroenterology & Hepatology*, 1-19 . <http://doi.org/10.1038/s41575-020-0300-1>
- 9) Janjigian, Y., Shitara, K., Moehler, M., Garrido, M., Salman, P., Shen, L., Wyrwicz, L., Yamaguchi, K., Skoczylas, T., Bragagnoli, A., Liu, Tianshu., Schenker, M., Yáñez, P., Tehfé, M., Kowalyszyn, R., Karamouzis, M., Brugés, R., Zander, T., Pazo-Cid, R., Hitre, E., Feeney, K., Cleary, J., Poulart, V., Cullen, D., Lei, M., Xiao, H., Kondo, K., Li, Mingshun., & Ajani, J. (2021). First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. *The Lancet*, 398 , 27-40 . [http://doi.org/10.1016/S0140-6736\(21\)00797-2](http://doi.org/10.1016/S0140-6736(21)00797-2)
- 10) Li, Jin., Qin, S., Xu, Jianming., Xiong, J., Wu, Changping., Bai, Y., Liu, Wei., Tong, J., Liu, Yunpeng., Xu, R., Wang, Zhehai., Wang, Qiong., Ouyang, X., Yang, Yan., Ba, Y., Liang, Jun., Lin, Xiaoyan., Luo, D., Zheng, R., Wang, Xin., Sun, G., Wang, Li-wei., Zheng, Leizhen., Guo, Hong., Wu, Jingbo., Xu, N., Yang, Jianwei., Zhang, Hong-gang., Cheng, Ying., Wang, Ningju., Chen, Lei., Fan, Zhi-lu., Sun, Piaoyang., & Yu, Hao. (2016). Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 34 13 , 1448-54 . <http://doi.org/10.1200/JCO.2015.63.5995>
- 11) Massad, L. Stewart., Einstein, M., Huh, W., Katki, H., Kinney, W., Schiffman, M., Solomon, D., Wentzensen, N., Lawson, H., & Massad, S. (2013). 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors.. *Obstetrics and gynecology*, 121 4 , 829-46 . <http://doi.org/10.1097/AOG.0b013e3182883a34>
- 12) Moffitt, Richard A., Marayati, Raoud., Flate, Elizabeth L., Volmar, Keith E., Loeza, S. G. H., Hoadley, K., Rashid, N., Williams, Lindsay A., Eaton, Samuel C., Chung, Alexander H., Smyla, Jadwiga K., Anderson, Judy M., Kim, Hong Jin., Bentrem, D., Talamonti, M., Iacobuzio-Donahue, C., Hollingsworth, Michael A., & Yeh, Jen Jen. (2015). Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. *Nature genetics*, 47 , 1168 - 1178 . <http://doi.org/10.1038/ng.3398>
- 13) Sato, Toshiro., Stange, D., Ferrante, M., Vries, R., Es, J. van., Brink, Stieneke van den., Houdt, W. V. van., Pronk, A., Gorp, J. V. van., Siersema, P., & Clevers, H. (2011). Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium.. *Gastroenterology*, 141 5 , 1762-72 . <http://doi.org/10.1053/j.gastro.2011.07.050>
- 14) Shaheen, N., Falk, G., Iyer, P., & Gerson, L. (2016). ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. *The American Journal of Gastroenterology*, 111 , 30-50 . <http://doi.org/10.1038/ajg.2015.322>
- 15) Tempero, M., Malafa, M., Al-Hawary, M., Asbun, H., Bain, Andrew J., Behrman, S., Benson, A., Binder, E., Cardin, D., Cha, Charles., Chiorean, E., Chung, V., Czito, B., Dillhoff, Mary E., Dotan, E., Ferrone, C., Hardacre, J., Hawkins, W., Herman, J., Ko, A., Komanduri, S., Koong, A., Loconte, N., Lowy, A., Moravek, C., Nakakura, E., O'Reilly, E., Obando, Jorge V., Reddy, S., Scaife, C., Thayer, S., Weekes, C., Wolff, R., Wolpin, B., Burns, J., & Darlow, S.

The Histopathology and Treatment Strategies of Adenocarcinoma

- (2017). Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.. Journal of the National Comprehensive Cancer Network : JNCCN , 15 8 , 1028-1061 . <http://doi.org/10.6004/jnccn.2017.0131>
- 16) Tempero, Margaret., Malafa, M., Chiorean, E. G., Czito, B., Scaife, C., Narang, A., Fountzilias, Christos., Wolpin, B., Al-Hawary, M., Asbun, H., Behrman, Stephen W., Benson, Al B., Binder, Ellen F., Cardin, D., Cha, Charles., Chung, V., Dillhoff, M., Dotan, E., Ferrone, C., Fisher, G., Hardacre, J., Hawkins, William., Ko, Andrew H., Loconte, N., Lowy, Andrew M., Moravek, C., Nakakura, E., O'Reilly, Eileen M., Obando, Jorge V., Reddy, S., Thayer, S., Wolff, Robert A., Burns, Jennifer L., & Zuccarino-Catania, Griselda. (2019). Pancreatic Adenocarcinoma, Version 1.2019.. Journal of the National Comprehensive Cancer Network : JNCCN , 17 3 , 202-210 . <http://doi.org/10.6004/jnccn.2019.0014>
- 17) Travis, W., Brambilla, E., Nicholson, A., Yatabe, Y., Austin, J., Beasley, M., Chirieac, L., Dacic, S., Duhig, E., Flieder, D., Geisinger, K., Hirsch, F., Ishikawa, Y., Kerr, K., Noguchi, M., Pelosi, G., Powell, C., Tsao, M., & Wistuba, I. (2015). The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer* , 10 9 , 1243-1260 . <http://doi.org/10.1097/JTO.0000000000000630>
- 18) Travis, W., Brambilla, E., Noguchi, M., Nicholson, A., Geisinger, K., Yatabe, Y., Beer, D., Powell, C., Riely, Gregory., Schil, P. V. Van., Garg, K., Austin, J., Asamura, H., Rusch, V., Hirsch, F., Scagliotti, G., Mitsudomi, T., Huber, R., Ishikawa, Y., Jett, J., Sanchez-Cespedes, M., Sculier, J., Takahashi, Takashi., Tsuboi, M., Vansteenkiste, J., Wistuba, I., Yang, Pan-Chyr., Aberle, D., Brambilla, C., Flieder, D., Franklin, W., Gazdar, A., Gould, M., Hasleton, P., Henderson, D., Johnson, B., Johnson, David H., Kerr, K., Kuriyama, K., Lee, J. S., Miller, V., Petersen, I., Roggli, V., Rosell, R., Saijo, N., Thunnissen, E., Tsao, M., & Yankelewitz, David. (2011). International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. *Journal of Thoracic Oncology* , 6 , 244-285 . <http://doi.org/10.1097/JTO.0b013e318206a221>
- 19) Yang, J., Wu, Yi-long., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, Caicun., Hu, Cheng-ping., O'Byrne, K., Feng, Jifeng., Lu, Shun., Huang, Yunchao., Geater, Sarayut Lucien., Lee, K., Tsai, C., Gorbunova, V., Hirsh, V., Bennouna, J., Orlov, S., Mok, T., Boyer, M., Su, W., Lee, K., Kato, T., Massey, D., Shahidi, M., Zazulina, V., & Sequist, L. (2015). Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.. *The Lancet. Oncology* , 16 2 , 141-51 . [http://doi.org/10.1016/S1470-2045\(14\)71173-8](http://doi.org/10.1016/S1470-2045(14)71173-8)
- 20) Ychou, M., Boige, V., Pignon, J., Conroy, T., Bouché, O., Lebreton, G., Ducourtieux, M., Bedenne, L., Fabre, J., Saint-Aubert, B., Genève, J., Lasser, P., & Rougier, P. (2011). Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* , 29 13 , 1715-21 . <http://doi.org/10.1200/JCO.2010.33.0597>